glp 1 covered by blue cross Indiana expands access to GLP-1s for Medicaid recipients with obesity BCBSM pulling back on GLP-1

Fatigue Reported by some patients when beginning treatment, lasting days to weeks

KLOW vs GLOW for Multi-Pathway Tissue Repair Studies When researchers need to isolate the contribution of the melanocortin anti-inflammatory pathway to overall tissue repair outcomes, klow vs glow peptide comparison designs provide the cleanest experimental approach

Note on humans: These benefits are not established in humans no completed clinical trials exist [1]

Drug Interactions: All vasopressors should be used cautiously in patients taking monoamine oxidase (MAO) inhibitors

First clinical trial to investigate the efficacy and safety of combined SGLT2 inhibitor and GLP-1R agonist therapy in patients with T2DM, suggesting additive or synergistic effects on weight loss